Enzo Biochem, Inc. announced the appointments of Hamid Erfanian and Bradley Radoff to the Company's Board of Directors (the “Board”), effective immediately. The Company also announced that directors Dov Perlysky and Rebecca Fischer will step down from the Board immediately to facilitate a smooth transition for the new Board members. Dr. Mary Tagliaferri will become the Board's lead independent director.

Messrs. Erfanian and Radoff will stand for election at Enzo Biochem's upcoming annual meeting (the “Annual Meeting”). The Company will also place a Board declassification proposal on the agenda at the upcoming Annual Meeting.

Mr. Erfanian was named Chief Executive Officer of Enzo Biochem in October 2021 and joined the Company in November 2021. He was most recently Chief Commercial Officer of EUROIMMUN, a PerkinElmer Company, and previously served as Chief Executive Officer of its US subsidiary. Prior to EUROIMMUN, Mr. Erfanian held executive and senior positions at several notable diagnostics companies including Diagnostica Stago, Beckman Coulter, and Abbott Laboratories.

Earlier in his career, Mr. Erfanian worked at leading diagnostic laboratory testing companies Quest Diagnostics and Laboratory Corporation of America. Mr. Radoff is a proven investor and seasoned public company director with significant experience in the areas of corporate governance, capital allocation, operational turnarounds and strategic reviews. Mr. Radoff has held roles at some of the world's top asset management firms and financial institutions, including Citadel and Third Point.

He currently serves on the Board of VAALCO Energy, Inc. and Harte Hanks, Inc. Mr. Radoff previously served as a director of Support.com, Inc. and Pogo Producing Company. The Board accepted the resignations of Dov Perlysky and Rebecca Fischer from the Board and each of its committees. Mr. Radoff will serve as Chairman of the Audit Committee of the Board and a member of the Nominating Committee and Compensation Committee of the Board.